Who Paid My Doc
Myron Brand
Gastroenterology New Haven, CT Medical Doctor
NPI 1336280080 CMS profile 105728
40 Temple St, Suite 4A, New Haven, CT 06510
General payments
$60,397
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Myron Brand of New Haven, CT is reported in the CMS Open Payments database as having received $60,397 across 536 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $20 | 1 | |
| 2022 | General | $8,256 | 148 | |
| 2021 | General | $3,617 | 126 | |
| 2020 | General | $15,464 | 82 | |
| 2019 | General | $33,041 | 179 |
Beside peers
- Myron Brand
- Gastroenterology median
- Middle half of Gastroenterology
- National median
In program year 2025, general payments to Myron Brand were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.
Show as a table
| Year | Myron Brand | Gastroenterology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $33,041 | $417 | $126–$1,100 | $163 |
| 2020 | $15,464 | $224 | $74–$624 | $114 |
| 2021 | $3,617 | $352 | $106–$1,054 | $132 |
| 2022 | $8,256 | $448 | $129–$1,270 | $149 |
| 2023 | $20 | $533 | $150–$1,390 | $160 |
| 2024 | $0 | $605 | $160–$1,606 | $164 |
| 2025 | $0 | $639 | $167–$1,700 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,606
Drug cost
$3,134,205
Branded share of claims
36.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Stelara Ustekinumab | Brand | 49 | $1,313,362 | |
| Gattex Teduglutide | Brand | 13 | $601,865 | |
| Rinvoq Upadacitinib | Brand | 31 | $360,484 | |
| Humira(Cf) Pen Adalimumab | Brand | 29 | $339,282 | |
| Creon Lipase/Protease/Amylase | Brand | 22 | $140,522 | |
| Mesalamine | Generic | 202 | $127,675 | |
| Dupixent Syringe Dupilumab | Brand | 14 | $104,782 | |
| Dexlansoprazole Dr Dexlansoprazole | Brand | 71 | $28,562 | |
| Linzess Linaclotide | Brand | 13 | $16,610 | |
| Budesonide Er Budesonide | Brand | 13 | $16,482 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$259,257
Medicare patients
330
Services billed
11,142
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Ischemic heart disease | 29% | |
| Diabetes | 23% | |
| Chronic kidney disease | 20% | |
| Depression | 20% | |
| Cancer | 19% | |
| Osteoporosis | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, vedolizumab, 1 mg J3380 | Office | 12 | 7,200 | $125,063 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 12 | 1,620 | $40,358 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
536 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gastroenterology in Connecticut
Related records
Gastroenterology in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Gastroenterology
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.